View article

[Lys(B28), Pro(B29)]‐human insulin (lispro) is an insulin analogue with a reduced capacity for self‐association and faster absorption from subcutaneous injection sites. We hypothesized that administration of lispro closer to a meal would result in better glucose control than that achieved with regular insulin.

This trial used a randomized crossover design that consisted of a period of metabolic stabilization lasting 9 days followed by an evaluation period lasting 5 days. The patients received weight‐maintenance diets, and insulin doses were adjusted as needed. Calorie intake, insulin dose, and activities were kept constant once the evaluation period began. During the evaluation period, we varied the time between insulin injection and mealtime and assessed glucose control.

During the evaluation period, the lowest mean glucose concentrations were 117.9 mg/dl for lispro and 119.8 mg …